These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 849701)

  • 21. A butyrophenone (haloperidol) for the treatment of institutionalized patients.
    Lapolla A; Nash LR
    Int J Neuropsychiatry; 1966 Apr; 2(2):129-34. PubMed ID: 5335397
    [No Abstract]   [Full Text] [Related]  

  • 22. [Controlled comparison of nalorphine with haloperidol in acute psychoses of the schizophrenic group ].
    Svestka J; Náhunek K; Cesková E; Rysánek R
    Cesk Psychiatr; 1982 Jun; 78(3):159-66. PubMed ID: 6749311
    [No Abstract]   [Full Text] [Related]  

  • 23. Extrapyramidal symptoms and signs in first-episode, antipsychotic exposed and non-exposed patients with schizophrenia or related psychotic illness.
    Honer WG; Kopala LC; Rabinowitz J
    J Psychopharmacol; 2005 May; 19(3):277-85. PubMed ID: 15888513
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical evaluation of haloperidol in geriatric patients.
    Tobin JM; Brousseau ER; Lorenz AA
    Geriatrics; 1970 Jun; 25(6):119-22. PubMed ID: 4915764
    [No Abstract]   [Full Text] [Related]  

  • 25. Anticholinergic agents for prophylaxis of neuroleptic-induced dystonic reactions: a prospective study.
    Sramek JJ; Simpson GM; Morrison RL; Heiser JF
    J Clin Psychiatry; 1986 Jun; 47(6):305-9. PubMed ID: 2872206
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Haloperidol decanoate as a replacement for maintenance therapy with intramuscular fluphenazine decanoate in schizophrenia and other chronic psychoses.
    Roose K
    Acta Psychiatr Belg; 1982; 82(2):216-23. PubMed ID: 7180558
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Orphenadrine plasma levels and amelioration of extrapyramidal side effects in schizophrenic patients treated with haloperidol.
    Altamura AC; Buccio M; Colacurcio F; Colombo G; Terzi A
    Acta Neurol (Napoli); 1986 Feb; 8(1):19-26. PubMed ID: 3962752
    [No Abstract]   [Full Text] [Related]  

  • 28. Use of hypnosis in EPS-associated anxiety.
    Amen DG
    J Clin Psychiatry; 1986 Feb; 47(2):98. PubMed ID: 3944075
    [No Abstract]   [Full Text] [Related]  

  • 29. Safe use of haloperidol in acute intermittent porphyria.
    Ibrahim ZY; Carney MM
    Ann Pharmacother; 1995 Feb; 29(2):200. PubMed ID: 7756725
    [No Abstract]   [Full Text] [Related]  

  • 30. [Clinical experience with bromperidol in chronic psychoses].
    Bellomo LE; Rosset N; Tellarini L; Forconesi N
    Acta Psiquiatr Psicol Am Lat; 1988 Sep; 34(3):230-6. PubMed ID: 3071092
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma concentrations of haloperidol and prolactin and clinical outcome in acutely psychotic patients.
    Aschauer HN; Schönbeck G; Langer G; Koinig G; Resch F; Hatzinger R; Chaudry HR; Sieghart W
    Pharmacopsychiatry; 1988 Sep; 21(5):246-51. PubMed ID: 3227055
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Basic principles of rapid neuroleptization.
    Mason AS; Granacher RP
    Dis Nerv Syst; 1976 Oct; 37(10):547-51. PubMed ID: 9267
    [No Abstract]   [Full Text] [Related]  

  • 33. Does a therapeutic window for plasma haloperidol exist?: Preliminary Chinese data.
    Potkin SG; Shen YC; Zhou DF; Pardes H; Shu L; Phelps B; Poland R
    Psychopharmacol Bull; 1985; 21(1):59-61. PubMed ID: 3983339
    [No Abstract]   [Full Text] [Related]  

  • 34. [Flupenthixol versus haloperidol in acute psychotic episodes].
    Parent M; Toussaint C
    Acta Psychiatr Belg; 1982; 82(6):617-31. PubMed ID: 7183131
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficient management of the acute psychotic patient: stabilization and maintenance with haloperidol.
    Garfinkel PE
    Proc R Soc Med; 1976; 69 suppl 1(Suppl 1):26-31. PubMed ID: 1019144
    [No Abstract]   [Full Text] [Related]  

  • 36. Serum haloperidol concentrations and clinical response in acute psychosis.
    Miller DD; Hershey LA; Duffy JP; Abernethy DR; Greenblatt DJ
    J Clin Psychopharmacol; 1984 Dec; 4(6):305-10. PubMed ID: 6511996
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of haloperidol in drug refractory patients.
    Ban TA; Lehmann HE
    Int J Neuropsychiatry; 1967 Aug; 3():Suppl 1:78-86. PubMed ID: 4383142
    [No Abstract]   [Full Text] [Related]  

  • 38. Short-term double-blind trial of pipothiazine palmitate and haloperidol in the acute phase of schizophrenia.
    Bechelli LP; Navas-Filho F
    Encephale; 1986; 12(3):121-5. PubMed ID: 2876879
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Haloperidol update: 1975.
    Ayd FJ
    Proc R Soc Med; 1976; 69 suppl 1(Suppl 1):14-22. PubMed ID: 1019142
    [No Abstract]   [Full Text] [Related]  

  • 40. Haloperidol blood levels and effects in schizophrenia and schizoaffective disorder: a progress report.
    Volavka J; Cooper TB; Meisner M; Bitter I; Czobor P; Jaeger J
    Psychopharmacol Bull; 1990; 26(1):13-7. PubMed ID: 2371368
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.